Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.
Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.
The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...
Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...
Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...
Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...
Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback